ArticleJournal, genetic engineering & biotechnology2018
Assessment of Ki-67 as a potential biomarker in patients with breast cancer.
Article in Journal, genetic engineering & biotechnology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 67 citations in OpenAlex.
- A deep learning model based on multiphase DCE-MRI for preoperative prediction of Ki-67 expression in breast cancer.Frontiers in oncology · 2026Article
- Microbial community profiles in breast cancer and normal adjacent tissues: associations with clinicopathological characteristics.Translational cancer research · 2025Article
- The value of multiparametric MRI radiomics and machine learning in predicting preoperative Ki-67 expression level in breast cancer.BMC medical imaging · 2025Article
- Article
- A review of prognostic and predictive biomarkers in breast cancer.Clinical and experimental medicine · 2023Review
- Cyclin A2 and Ki-67 proliferation markers could be used to identify tumors with poor prognosis in African American women with breast cancer.Journal of cancer biology · 2023Article
- Magnetoelectric core-shell CoFeRSC advances · 2022Article
- Utility of Serum Ki-67 as a Marker for Malignancy in Dogs.Animals : an open access journal from MDPI · 2022Article
- Undetected αKlotho in serum is associated with the most aggressive phenotype of breast cancer.Molecular and clinical oncology · 2022Article
- ACSL4 as a Potential Target and Biomarker for Anticancer: From Molecular Mechanisms to Clinical Therapeutics.Frontiers in pharmacology · 2022Review
- Breast Cancer and p16: Role in Proliferation, Malignant Transformation and Progression.Healthcare (Basel, Switzerland) · 2021Article
- Impact of Stilbenes as Epigenetic Modulators of Breast Cancer Risk and Associated Biomarkers.International journal of molecular sciences · 2021Review
- Article
- Ki-67 and Its Relation With Complete Pathological Response in Patients With Breast Cancer.Cureus · 2021Article
- Article
- Human-interpretable image features derived from densely mapped cancer pathology slides predict diverse molecular phenotypes.Nature communications · 2021Article
- Biocompatibility and cytotoxicity in vitro of surface-functionalized drug-loaded spinel ferrite nanoparticles.Beilstein journal of nanotechnology · 2021Article
- Th2 cell infiltrations predict neoadjuvant chemotherapy response of estrogen receptor-positive breast cancer.Gland surgery · 2021Article
- A comparative study between Ki67 positive versus Ki67 negative females with breast cancer: Cross sectional study.Annals of medicine and surgery (2012) · 2020Article
- An Overview of the Antioxidant Effects of Ascorbic Acid and Alpha Lipoic Acid (in Liposomal Forms) as Adjuvant in Cancer Treatment.Antioxidants (Basel, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is the most common cancer in females, it accounts for one third of all malignancies affecting women. Appropriate biomarkers play significant role in predicting the prognosis and decide the specific therapy to each patient. In this study we aimed at evaluating the value of Ki-67 as a prognostic marker in breast cancer patients and to analyze the associations between Ki-67 and their clinicopathological parameters. This study included 92 patients with developed non metastatic breast cancer and 10 women had benign breast tumor served as controls. We measured the serum level by ELISA technique and tissue expression of Ki-67 by immunohistochemical technique. Our results showed that there were no statistically significant differences in serum Ki-67 levels between the two studied groups. As for Ki-67expression in breast cancer cells, the score increases with increase of tumor size, grade, premenopausal, Ki-67 expression in estrogen and progesterone receptor positive tumors showed lower values than estrogen and progesterone negative tumors, while higher Ki-67 expression was more frequently associated with HER2-positive. In conclusion; our study supports the finding that tissue Ki-67 expression may add prognostic information to that obtained from classical prognostic factors and can provide data of significant value to other important prognostic indicators such as pathological grading, and axillary lymph node involvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.